المؤلفون: Gilles Ndayisaba (11860569), Adoke Yeka (18017), Kwaku Poku Asante (8943890), Martin P. Grobusch (10048320), Etienne Karita (62290), Henry Mugerwa (301399), Stephen Asiimwe (819912), Abraham Oduro (391468), Bakary Fofana (3539657), Seydou Doumbia (65941), Jay Prakash Jain (2233621), Sarita Barsainya (11860572), Gerd A. Kullak-Ublick (7413455), Guoqin Su (11860575), Esther K. Schmitt (2283112), Katalin Csermak (11860578), Preetam Gandhi (11860581), David Hughes (47111)

مصطلحات موضوعية: Medicine, Cell Biology, Immunology, Cancer, Infectious Diseases, Virology, Environmental Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, Cipargamin, Malaria, KAE609, Hepatic safety, Phase II randomized controlled trial, Plasmodium falciparum

Relation: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Hepatic_safety_and_tolerability_of_cipargamin_KAE609_in_adult_patients_with_Plasmodium_falciparum_malaria_a_randomized_phase_II_controlled_dose-escalation_trial_in_sub-Saharan_Africa/17304822

الاتاحة: https://doi.org/10.6084/m9.figshare.17304822.v1